Miguel Lecumberri

MAJ Invest Equity A/S (MAJ Invest) is a private equity subsidiary of Fondsmæglerselskabet MAJ Invest A/S, itself a subsidiary of MAJ Invest Holding A/S. The firm was founded in 2005 and is headquartered in Copenhagen, Denmark.

Fondsmæglerselskabet Maj Invest A/S (FM Invest) is the wholly-owned asset management subsidiary of Maj Invest Holding A/S in Denmark. The firm was founded in 2005 and is headquartered in Copenhagen. FM Invest provides advice on strategic asset allocation and asset management of securities listed on regulated markets for institutional clients and serves as the investment adviser to the Maj Invest mutual funds in Denmark and Luxembourg, which are owned by their members. They also offer wealth management services to wealthy individuals, companies and funds.

Vivostat A/S provides cardiac, thoracic and orthopaedic surgery medical devices. It offers vivostat system, an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin. Its products include Vivostat autologous fibrin sealant for various settings in surgical areas, transfusion centers, or blood banks and Vivostat platelet rich fibrin, which utilizes the patient's own blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors that stimulates the healing of chronic wounds, as well as provides application devices. The compnay was founded in 2001 by Tom Bjerg Lauritzen and Niels Hvid and is headquartered in Alleroed, Denmark.

CAPRES A/S develops, manufactures, and sells micro-scale electromechanical components and systems. It specializes in technology that allows direct measurement of sheet resistance, Hall Mobility, and Active Carrier Density. The company was founded by Peter Folmer Nielsen, Christian Leth Petersen, and Ulrik Quade in 1999 and is headquartered in Kongens Lyngby, Denmark.

Novo Nordisk Scandinavia AB develops, manufactures and markets pharmaceutical products and services. Its products include medicine for diabetes, hemophilia, growth disorders, and hormone therapy. The company is headquartered in Malmö, Sweden.

Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

Den Sociale Kapitalfond Invest I K/S is a social impact fund investing in small and mid-size companies located in Denmark and Sweden. The fund targets companies operating in industries such as manufacturing, consumer durables and services, and with annual revenues of DKK 30 to 200 million. It provides financing for growth-stage capital requirements, and makes co-investments. The fund looks to take minority stake positions, and a seat on the board.

Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020.

Caissa Group ApS provides services in research design programs.